| Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor [ID6305] | Technology appraisal guidance |
| Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117] | Technology appraisal guidance |
| Leriglitazone for treating X-linked andrenoleukodystrophy [TSID9996] | Technology appraisal guidance |
| Letetresgene autoleucel for treating NY-ESO-1 advanced unresectable synovial sarcoma in people aged 10 and over or NY-ESO-1 advanced unresectable myxoid round cell liposarcoma in adults [TSID10652] | Technology appraisal guidance |
| Linerixibat for treating pruritus in people with primary biliary cholangitis [ID6265] | Technology appraisal guidance |
| Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017] | Technology appraisal guidance |
| Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment [ID3869] | Technology appraisal guidance |
| Lisocabtagene maraleucel for treating relapsed or refractory low-grade B-cell follicular lymphoma after 1 or more treatments [ID6564] | Technology appraisal guidance |
| Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer PD [ID6526] | Technology appraisal guidance |
| Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870] | Technology appraisal guidance |
| Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315] | Technology appraisal guidance |
| Machine perfusion devices for liver transplant | Health technology evaluation |
| Marstacimab for treating severe haemophilia A or B in people 12 years and over with inhibitors to factor-replacement therapy
[TSID12143] | Technology appraisal guidance |
| Mavorixafor for treating WHIM syndrome [ID3946] | Technology appraisal guidance |
| Mepolizumab for reducing eosinophilic exacerbations of chronic obstructive pulmonary disease [ID1237] | Technology appraisal guidance |
| Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment [ID6513] | Technology appraisal guidance |
| Middle meningeal artery embolisation for chronic subdural haematomas | Interventional procedures guidance |
| MIM8 for preventing bleeding episodes in haemophilia A in people 1 year and over [ID6400] | Technology appraisal guidance |
| Mirabegron for treating neurogenic detrusor overactivity in people aged 3 to 17 [TSID10730] | Technology appraisal guidance |
| Navepegritide for treating achondroplasia in people 2 to 15 years [ID6538] | Technology appraisal guidance |
| Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769] | Technology appraisal guidance |
| Nedosiran treating primary hyperoxaluria type 1 in people 6 years and over [TSID11777] | Technology appraisal guidance |
| Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078] | Technology appraisal guidance |
| Neuro-Cells stem-cell treatment for traumatic spinal cord injury [TSID12048] | Technology appraisal guidance |
| Nicardipine (Nicaplant) for aneurysmal subarachnoid haemorrhage patients undergoing aneurysm clipping [TSID10593] | Technology appraisal guidance |
| Nipocalimab for treating generalised myasthenia gravis [ID6562] | Technology appraisal guidance |
| Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer [TSID12044] | Technology appraisal guidance |
| Niraparib with dostarlimab for maintenance treatment of advanced or recurrent endometrial cancer [ID6316] | Technology appraisal guidance |
| Niraparib with pembrolizumab for maintenance treatment of advanced non-small-cell lung cancer after platinum-based chemotherapy with pembrolizumab [ID6345] | Technology appraisal guidance |
| Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321] | Technology appraisal guidance |
| Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma [TSID9659] | Technology appraisal guidance |
| Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239] | Technology appraisal guidance |
| Nivolumab–relatlimab for adjuvant treatment of resected stage 3 or 4 melanoma in people 12 years and over [ID6475] | Technology appraisal guidance |
| Obicetrapib or obicetrapib–ezetimibe for treating primary heterozygous hypercholesterolaemia or mixed dyslipidaemia [ID6519] | Technology appraisal guidance |
| Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy [TSID11996] | Technology appraisal guidance |
| Olezarsen for treating familial chylomicronaemia
syndrome [TSID11993] | Technology appraisal guidance |
| Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912] | Technology appraisal guidance |
| Onasemnogene abeparvovec for treating spinal muscular atrophy in people 2 years and over [ID6556] | Technology appraisal guidance |
| Onasemnogene abeparvovec for treating spinal muscular atrophy in people 2 years and over [TSID12168] | Technology appraisal guidance |
| Ondansetron for treating alcohol-use disorder [ID6341] | Technology appraisal guidance |
| Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease TS ID 11941 | Technology appraisal guidance |
| Oral semaglutide for managing overweight and obesity [ID6188] | Technology appraisal guidance |
| Orforglipron for managing overweight and obesity [ID6516] | Technology appraisal guidance |
| Osimertinib for neoadjuvant treatment of EGFR mutation-positive resectable non-small-cell lung cancer [ID6472] | Technology appraisal guidance |
| OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152] | Highly specialised technology |
| Ovarian, fallopian tube, peritoneal cancer (platinum sensitive) - rucaparib (with nivolumab, maintenance, after 1 therapy) [ID6128] | Technology appraisal guidance |
| Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846] | Technology appraisal guidance |
| Pariglasgene brecaparvovec for treating glycogen storage disease type 1a in people 8 years and over [TSID11865] | Technology appraisal guidance |
| Patritumab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after 1 or 2 tyrosine kinase inhibitor treatment [ID6467] | Technology appraisal guidance |
| Pegargiminase with pemetrexed and cisplatin for untreated advanced malignant pleural
mesothelioma [ID1575] | Technology appraisal guidance |